Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravenous fentanyl kinetics

D A McClain, C C Hug

    Clinical Pharmacology and Therapeutics
    |July 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Fentanyl, a short-acting pain reliever, showed slow elimination from the body and fluctuating plasma levels in a study. These pharmacokinetic factors may explain prolonged respiratory depression after its use.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Intramuscular fat and inflammation differ in older adults: the impact of frailty and inactivity.

    The journal of nutrition, health & aging·2014
    Same author

    Regional muscle glucose uptake remains elevated one week after cessation of resistance training independent of altered insulin sensitivity response in older adults with type 2 diabetes.

    Journal of endocrinological investigation·2012
    Same author

    Increased insulin secretory capacity but decreased insulin sensitivity after correction of iron overload by phlebotomy in hereditary haemochromatosis.

    Diabetologia·2006
    Same author

    High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis.

    Diabetologia·2006
    Same author

    The pharmacokinetics of remifentanil in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass.

    Anesthesia and analgesia·2001
    Same author

    End-of-life issues and the anesthesiologist.

    International anesthesiology clinics·2001
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Clinical Pharmacology
    • Toxicology

    Background:

    • Fentanyl is a potent opioid analgesic.
    • Prolonged and recurrent ventilatory depression is a known adverse effect.
    • Understanding fentanyl's pharmacokinetics is crucial for safe clinical use.

    Purpose of the Study:

    • To investigate the pharmacokinetic profile of fentanyl.
    • To determine fentanyl excretion patterns.
    • To explore the relationship between fentanyl kinetics and prolonged respiratory effects.

    Main Methods:

    • Administered intravenous 3H-fentanyl (3.2 or 6.4 micrograms/kg) to 7 healthy male subjects.
    • Analyzed arterial blood and urine for unchanged fentanyl and total radioactivity.
    • Determined fentanyl plasma concentrations and elimination half-life (t1/2 beta).

    Related Experiment Videos

    Main Results:

    • Rapid initial plasma fentanyl decline (98.6% eliminated in 60 min).
    • Slow terminal elimination phase with a long half-life (t1/2 beta = 219 min).
    • Significant fluctuations in plasma fentanyl levels observed during elimination.
    • 85% of the dose recovered in urine and feces within 72 hours, with <8% as unchanged fentanyl.

    Conclusions:

    • Fentanyl's slow elimination and fluctuating plasma levels may contribute to prolonged and recurrent ventilatory depression.
    • Biotransformation is the primary elimination route, occurring mainly in the central compartment.
    • The slow return of fentanyl from peripheral tissues influences its prolonged effects.